Background: 3B3 is a high-affinity anti-gp120 antibody that neutralizes a wide range of primary and laboratory isolates of HIV-1. The parental antibody was isolated from a combinatorial phage display library constructed from bone marrow RNA of an HIV-infected individual. We have generated a highly active immunotoxin using the 3B3 single-chain Fv (scFv) 
Introduction
Since the initial isolation of HIV in 1983 and its identification as the causative agent of AIDS (1, 2) , tremendous efforts have been made to understand the cause and pathogenesis of AIDS, but an effective therapy leading to the cure of PE38 that was expressed in E. coli and purified to near homogeneity. Results: 3B3(Fv)-PE38 binds with the same affinity as the parental Fab antibody to the MN strain of gp 120. The immunotoxin specifically kills a gp120-expressing transfected cell line and a chronically HIV-infected lymphocytic cell line. The immunotoxin is very stable at 37°C, retaining 80% of its original activity after 24 hr. Conclusions: Potent immunotoxins such as 3B3(Fv)-PE38 could be utilized in combination with multidrug cocktails that limit viral replication to help reduce viral reservoirs in patients with AIDS. this disease is still in the future. To date, there are several therapeutic drugs available to treat HIVinfected patients, and these lead to prolongation of life and control of symptoms. The major approaches for the treatment of individuals with AIDS or HIV infections are the administration of drugs such as a reverse transcriptase inhibitor, AZT (3 '-azido-3'-deoxythymidine), or ddl (2', 3-dideoxyinosine), which act by inhibiting synthesis of the proviral genome after the virion has entered the host cell, and protease inhibitors, which block production of infectious virions. Although these agents can effectively inhibit HIV spread in vitro and in vivo, they do not kill those cells that are already infected. Recently, a highly active antiretroviral therapy (HAART) has shown encouraging results on reduction of viral loads in lymphoid tissues of HIV-infected patients (3, 4) . In this approach, a cocktail consisting of an HIV-1 protease inhibitor and two reverse transcriptase inhibitors (RIs) is administered for the treatment of HIV-infected patients. Although significant progress has been made recently in the treatment of HIV-1 infection, we are not yet close to a cure for AIDS.
Immunotoxins are potent cell-killing agents composed of either antibodies or antibody fragments attached to protein toxins made by bacteria or plants (5, 6 In this study, we have made a recombinant toxin containing the Fv portion of an antibody 3B3 that has a high affinity and a broad crossreactivity with many laboratory and clinical isolates of HIV. The parental antibody was isolated from a combinatorial phage display library constructed from bone marrow RNA of an HIVinfected individual (8) and that neutralizes many different laboratory strains of HIV-1 as well as many primary isolates (9) (10) (11) . The antibody reacts with the conserved CD4-binding site of gpl20, the external subunit of the envelope glycoprotein (12 GGT CCC CTG GCC AAA AGT GTA CGA GGA GGC ACC ATA-3') was used to amplify the lightchain Fv region. The plasmid pTKB21.18 that encodes VH and VL domains of 3B3 antibody connected by a 15 amino acid linker and fused to PE38 was generated by spliced PCR using the purified individual VH and VL PCR fragments through the primers T128 and T131 and was cloned into the NdeI-HindIII site of pUL17. The NdeI-HindIII sites fused the inserted fragment in frame to the PE38, the truncated form of Pseudomonas exotoxin (13) . The vector contains the T7 promoter for expression in Studier's E. coli BL21(ADE3) expression system (14) . The expression plasmid was confirmed to be correct by DNA sequencing on an ABI 373A sequencer using the Dydeoxy chain terminator sequencing kit.
The immunotoxin 3b3(Fv)-PE38 was expressed in E. coli BL21(ADE3). It was then accumulated in inclusion bodies (IBs) and purified as an active immunotoxin molecule, following the method as previously described for other recombinant immunotoxins (15, 16 The binding affinity of the parental antibody 3B3 Fab, from which the 3B3(Fv) fragment is made, was improved by complementarity determining region (CDR) walking mutagenesis using phage display technology (12) . Frequently, scFvs posses lower binding affinity than the parental whole antibody or Fab (18 attached to a truncated form of Pseudomonas exotoxin A (19) , and compared its activity with 3B3(Fv)-PE38 immunotoxin. As shown in Figure 3A and Figure 3B and Table 2 show that 3B3(Fv)-PE38 can kill 8E5 cells very effectively with an 
Discussion
The HIV antigen envelope glycoproteins (gp120 and gp4l) are the only viral proteins displayed on the HIV-infected cell surface that can be recognized by specific antibodies. Since gpl20 is exposed on the cell surface of the infected cell, major efforts have been made to target the HIVinfected cells by generating antibodies against the gp120 glycoprotein. Although there is a high degree of inter-isolate sequence variability of gpl20, there are a few conserved regions to which antibodies can be generated. Antibody IgGlb12 was isolated from a combinatorial phage display library constructed from bone marrow RNA of an HIV-infected individual (8) . This antibody is directed to the CD4 binding site of gpl20, and unlike other monoclonal antibodies that are also directed to CD4 binding epitope, it can neutralize many different laboratory strains of HIV-1 as well as many primary isolates (9) (10) (11) . Both the potency and breadth of neutralization activity of 3B3 were improved over the parental antibody IgGlbl2 (12 (21) . The immunotoxin anti-gp4l and ricin immunoconjugate, which is directed against gp4l of HIV, has also been reported to be effective in vitro on HIV-infected T cells and monocytes (24) . But neither of these molecules have been examined in HIV-infected patients. The most extensively studied chimeric toxin, CD4-PE40, was generated in our laboratory (16) .
It is a recombinant chimeric protein containing CD4 linked to a 40,000 molecular weight form of Pseudomonas exotoxin A. CD4-PE40 was effective in killing an Env-expressing cell line and chronically HIV-infected cells (19) . Also, when CD4-PE40 was used in combination with reverse transcriptase inhibitors that block the viral replication cycles, a synergistic effect was observed, leading to elimination of infectious HIV from human T cell cultures (25) . On the basis of these data, preclinical development of CD4-PE40 was carried out and it was found to be very well tolerated by monkeys, so that 250 ,ug/kg could be administered daily for 10 days without serious toxicity. Subsequently, phase I clinical trials were performed (26, 27) . Surprisingly, CD4-PE40 demonstrated very high toxicity in HIV-infected patients with a maximum tolerated dose of only 10 ,g/kg. The major side effect was liver toxicity. No evidence of anti-HIV effect of this protein in this trial was obtained, probably because of the low amount of the drug that could be given to patients. The toxicity of CD4-PE40 is probably due to the CD40-PE40 is probably due to the CD4 portion directing the immunotoxin to the liver, since we have subsequently given several other recombinant immunotoxins to patients at doses of up to 50 jig/kg without observing doselimiting liver toxicity (our unpublished data). In addition, a chemical conjugate of PE38 with a whole monoclonal antibody has been given in doses of up to 100 ,ug/kg without liver toxicity (7) . 3B3(Fv)-PE38 is about 20-to 30-fold more effective in killing gp120-expressing and HIVinfected cells in vitro than CD4-PE40 and should be devoid of the nonspecific toxicity observed with CD4-PE40. We believe that immunotoxins such as 3B3 (Fv) -PE38 can have significant utility when used with existing multiple drug strategies. "Triple-drug" therapy could be utilized to remove the soluble antigen, Env, and competing antibodies from the infected patient, since viral titers and competing antibody titers crash following their application. 
